Clinical Trials Logo
  1. Home
  2. Essential Hypertension
  3. NCT00139698
  4. Details
NCT00139698 Clinical Trial

Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

Essential Hypertension Clinical Trial

— OSCAR  

Official title:
A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00139698
Other study ID # A0021002
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2005
Est. completion date July 2006

Study information
Verified date December 2018
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension

Recruitment information / eligibility
Status Completed
Enrollment 410
Est. completion date July 2006
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Subject has mild to moderate hypertension

Exclusion Criteria:

- History of secondary hypertension

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• olmesartan alone or in combination with hydrochlorothiazide

Locations
Country Name City State
Pfizer Investigational Site
Colombia Pfizer Investigational Site Barranquilla Atlantico
Colombia Pfizer Investigational Site Bogota Cundinamarca
Colombia Pfizer Investigational Site Cali Valle Del Cauca
Colombia Pfizer Investigational Site Cartagena Atlantico
Colombia Pfizer Investigational Site Medellin Antioquia
Ecuador Pfizer Investigational Site Escobedo Guayas
Ecuador Pfizer Investigational Site Quito Pichincha
Hong Kong Pfizer Investigational Site NT
Hong Kong Pfizer Investigational Site Shatin, NT
Indonesia Pfizer Investigational Site Jakarta
Indonesia Pfizer Investigational Site Jakarta
Indonesia Pfizer Investigational Site Jakarta
Indonesia Pfizer Investigational Site Surabaya
Malaysia Pfizer Investigational Site Kuching Sarawak
Malaysia Pfizer Investigational Site Seremban Negeri Sembilan
Philippines Pfizer Investigational Site Quezon
Philippines Pfizer Investigational Site San Juan Metro Manila
Singapore Pfizer Investigational Site Singapore
Singapore Pfizer Investigational Site Singapore
Taiwan Pfizer Investigational Site Guei-Shan Shiang Tau-Yuan Shian
Taiwan Pfizer Investigational Site Kaohsiung
Taiwan Pfizer Investigational Site Taipei
Taiwan Pfizer Investigational Site Taipei
Thailand Pfizer Investigational Site Bangkok
Thailand Pfizer Investigational Site Bangkok
Thailand Pfizer Investigational Site Chiang Mai
Thailand Pfizer Investigational Site Khet Rajathevee Bangkok
Turkey Pfizer Investigational Site Bornova/Izmir
Turkey Pfizer Investigational Site Haseki/Istanbul
Turkey Pfizer Investigational Site S¿hhiye/Ankara
Turkey Pfizer Investigational Site Sihhiye/Ankara

Sponsors (1)
Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

Colombia,  Ecuador,  Hong Kong,  Indonesia,  Malaysia,  Philippines,  Singapore,  Taiwan,  Thailand,  Turkey, 

Outcome
Type Measure Description Time frame Safety issue
Primary Efficacy of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Secondary Safety and tolerability of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
See also
  Status Clinical Trial Phase
Recruiting NCT03708601 - Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
Not yet recruiting NCT05503953 - Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS Phase 3
Recruiting NCT05526703 - Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy Phase 3
Completed NCT06395194 - Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension Phase 3
Not yet recruiting NCT06418074 - Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity N/A
Completed NCT02890173 - Study of CS-3150 in Patients With Essential Hypertension Phase 3
Withdrawn NCT02096939 - Microvascular Function in Primary Aldosteronism N/A
Completed NCT02944734 - Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension Phase 2
Recruiting NCT01956786 - Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine Phase 2/Phase 3
Completed NCT02553512 - Helius in Hypertension-I: The UK Hypertension Registry N/A
Completed NCT01198249 - Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension Phase 1
Completed NCT01001572 - Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension Phase 3
Recruiting NCT00380289 - Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension N/A
Completed NCT00288184 - Uric Acid in Essential Hypertension in Children Phase 2
Completed NCT01289886 - Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects Phase 1
Not yet recruiting NCT06041529 - Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension Phase 4
Completed NCT04470830 - A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
Completed NCT00758524 - A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension Phase 2
Recruiting NCT05109013 - Juvenile Essential Arterial Hypertension and Vascular Function
Completed NCT00741585 - Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment Phase 4

External Links